Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>As we are heading into 2023, let us look back on the performance of some of our global healthcare stocks recommended throughout 2022.</li>
<li>Four stocks on which I am bullish, generated more than 50% return since their recommendations. 10 stocks on which I am bearish plunged more than 20%.</li>
<li>For 2023, investors should continue to focus on established healthcare companies, having strong and flexible balance sheet with muti-year revenue visibility.</li>
</ul>


As we are heading into 2023, let us look back on the performance of some of our global healthcare stocks recommended throughout 2022.
Four stocks on which I am bullish, generated more than 50% return since their recommendations. 10 stocks on which I am bearish plunged more than 20%.
For 2023, investors should continue to focus on established healthcare companies, having strong and flexible balance sheet with muti-year revenue visibility.


2022 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of KRX stocks as of Feb 27th. The aggregated short interest was USD15.4bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in HyundaiEng&amp;Const, LG H&amp;H, HyundaiAutoever, Samsung SDI, Hanmi Semi.</li>
</ul>


We analyzed the changes in short interest of KRX stocks as of Feb 27th. The aggregated short interest was USD15.4bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in HyundaiEng&amp;Const, LG H&amp;H, HyundaiAutoever, Samsung SDI, Hanmi Semi.


KRX Short Interest Weekly (Feb 27th): HyundaiEng&Const, LG H&H, HyundaiAutoever, Samsung SDI

<ul>
<li>We analyzed the changes in short interest of KRX stocks as of Feb 20th. The aggregated short interest was USD15.0bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in COWAY, Doosan Enerbility, Hanwha Ocean, Samsung F&amp;M Insurance, Samsung SDI.</li>
</ul>


We analyzed the changes in short interest of KRX stocks as of Feb 20th. The aggregated short interest was USD15.0bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in COWAY, Doosan Enerbility, Hanwha Ocean, Samsung F&amp;M Insurance, Samsung SDI.


KRX Short Interest Weekly (Feb 20th): COWAY, Doosan Enerbility, Hanwha Ocean, Samsung F&M Insurance

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Equity Capital Markets

Dongbang Medical / Equity Capital Markets

<ul>
<li>Dongbang Medical is getting ready to complete its IPO in Korea in February 2025. The IPO price range is from 9,000 won to 10,500 won. </li>
<li>According to the bankers' valuation, the expected market cap of the comps ranges from 191 billion won to 223 billion won.</li>
<li>Dongbang Medical specializes in the manufacturing and distribution of acupuncture needles, various cosmetic devices, and other medical devices. </li>
</ul>


Dongbang Medical is getting ready to complete its IPO in Korea in February 2025. The IPO price range is from 9,000 won to 10,500 won. 
According to the bankers' valuation, the expected market cap of the comps ranges from 191 billion won to 223 billion won.
Dongbang Medical specializes in the manufacturing and distribution of acupuncture needles, various cosmetic devices, and other medical devices. 


<ul>
<li>We analyzed the changes in short interest of KRX stocks as of Jan 3rd which has an aggregated short interest worth USD3.5bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Samsung Biologics (207940 KS).</li>
</ul>


We analyzed the changes in short interest of KRX stocks as of Jan 3rd which has an aggregated short interest worth USD3.5bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Samsung Biologics (207940 KS).


KRX Short Interest Weekly (Jan 3rd): Samsung Biologics

South Korea

BNC Korea Co, Ltd operates as a biological development company. The Company develops, manufactures and sells hyaluronic acid filler and other products. BNC Korea markets its products throughout Korea.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BNC Korea (256840 KS)

2022 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

From my coverage universe, two Taiwanese stocks generated 59% and 71% returns in nearly six months. New product launch and geography expansion are...

Tina Banerjee

KRX Short Interest Weekly (Feb 27th): HyundaiEng&Const, LG H&H, HyundaiAutoever, Samsung SDI

We analyzed KRX short interest report for the past week and highlighted short interest changes in HyundaiEng&Const, LG H&H, HyundaiAutoever,...

Ke Yan, CFA, FRM

KRX Short Interest Weekly (Feb 20th): COWAY, Doosan Enerbility, Hanwha Ocean, Samsung F&M Insurance

We analyzed KRX short interest report for the past week and highlighted short interest changes in COWAY, Doosan Enerbility, Hanwha Ocean, Samsung...

Ke Yan, CFA, FRM

Dongbang Medical IPO Preview

Dongbang Medical is getting ready to complete its IPO in Korea in February 2025. The IPO price range is from 9,000 won to 10,500 won.

Douglas Kim

KRX Short Interest Weekly (Jan 3rd): Samsung Biologics

We analyzed KRX short interest report for the past week and highlighted short interest changes in Samsung Biologics(207940 KS).

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)